Genmab and BioNTech to co-develop/co-own immuno-oncology projects; Collaboration expanded to new candidates
BioNTech AG and Genmab AS will work together to develop and commercialize bispecific antibodies in the area of immuno-oncology.
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.